GlassScriptPhysician profile
Benjamin Schwartz
NPI 1194188367
$7,421.75
in general payments reported to CMS, 2019-2025
59 companies · $1,788 in 2025
The $1,788 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,048 · 2023: $2,193 · 2024: $2,392 · 2025: $1,788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,774 · Education: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,773.53 |
| Education | $599.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $846.56 | 2022-2025 | |
| Incyte Corporation | $522.85 | 2022-2025 | Jakafi, Monjuvi, Zynyz |
| E.R. Squibb & Sons, L.L.C. | $448.83 | 2022-2025 | Opdivo |
| Janssen Biotech, INC. | $354.60 | 2023-2025 | Imbruvica, Rybrevant, Darzalex |
| Celgene Corporation | $353.28 | 2022-2024 | Reblozyl |
| Merck Sharp & Dohme LLC | $348.00 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $343.52 | 2025 | Imfinzi, Enhertu, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $311.72 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $267.69 | 2022-2025 | |
| Astellas Pharma US INC | $221.52 | 2023-2024 | Xospata, Vyloy |
| Genentech USA, INC. | $219.36 | 2023-2025 | Tecentriq, Alecensa, Polivy |
| Regeneron Healthcare Solutions, INC. | $210.55 | 2023-2024 | Libtayo |
| Daiichi Sankyo INC. | $189.33 | 2023-2025 | Enhertu, Vanflyta, Injectafer |
| Glaxosmithkline, LLC. | $148.39 | 2023-2025 | Ojjaara |
| Cti Biopharma Corp. | $147.06 | 2023 | Vonjo |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $145.37 | 2023-2025 | Xpovio |
| Steris Corporation | $141.55 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $137.74 | 2024-2025 | Fruzaqla |
| Rigel Pharmaceuticals, INC. | $137.62 | 2022-2025 | Rezlidhia, Gavreto, Tavalisse |
| Seagen INC. | $134.13 | 2022-2023 | Adcetris, Tukysa, Padcev |
| Kite Pharma, INC. | $129.94 | 2022-2023 | Yescarta |
| Sumitomo Pharma America, INC. | $85.13 | 2023-2025 | Orgovyx |
| Amgen INC. | $82.40 | 2022-2023 | Lumakras, Kyprolis, Blincyto |
| Sobi, INC | $77.66 | 2024-2025 | |
| Puma Biotechnology, INC. | $77.31 | 2022-2023 | |
| Abbvie INC. | $74.82 | 2024-2025 | |
| Lilly USA, LLC | $71.52 | 2023-2024 | Jaypirca, Verzenio, Retevmo |
| Blueprint Medicines Corporation | $71.15 | 2023-2025 | Ayvakit, Gavreto |
| Deciphera Pharmaceuticals INC. | $67.21 | 2023-2025 | Qinlock, Romvimza |
| Ipsen Biopharmaceuticals, INC | $66.27 | 2023-2024 | Onivyde, Tazverik |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.00 | 2024-2025 | Gilotrif |
| Caris Mpi, INC. | $63.26 | 2025 | Mi Cancer Seek |
| Pinnacle Biologics, INC | $61.47 | 2025 | Photofrin |
| Array Biopharma INC | $58.47 | 2022-2025 | Lorbrena, Braftovi, Mektovi |
| Aveo Pharmaceuticals, INC. | $52.12 | 2023-2024 | Fotivda |
| Tempus Ai, INC | $47.52 | 2025 | Xt Cdx |
| Eisai INC. | $47.23 | 2023 | |
| Myovant Sciences INC. | $46.87 | 2022 | |
| Genzyme Corporation | $46.56 | 2022-2023 | |
| Jazz Pharmaceuticals INC. | $45.94 | 2023-2024 | |
| Exelixis INC. | $43.62 | 2024 | Cabometyx |
| Pharmacyclics LLC, An Abbvie Company | $38.06 | 2023 | Imbruvica |
| Adaptive Biotechnologies Corporation | $37.28 | 2024 | Clonoseq |
| Emd Serono, INC. | $36.71 | 2024 | |
| Stemline Therapeutics INC. | $27.85 | 2023 | Orserdu |
| Fresenius Kabi USA, LLC | $26.47 | 2024 | Stimufend |
| Coherus Oncology, INC. | $22.61 | 2024 | |
| Amneal Pharmaceuticals LLC | $22.37 | 2024 | Neulasta, Avastin, Neupogen |
| Kyowa Kirin, INC. | $22.33 | 2022 | |
| Spectrum Pharmaceuticals INC. | $22.23 | 2025 | Rolvedon |
| Morphosys, US INC. | $21.87 | 2023 | Monjuvi |
| Taiho Oncology, INC. | $20.09 | 2022 | |
| Springworks Therapeutics, INC. | $17.93 | 2024 | Ogsiveo |
| Agios Pharmaceuticals, INC. | $17.29 | 2024 | Pyrukynd |
| Genentech, INC. | $16.97 | 2023 | Tecentriq |
| Beigene USA, INC. | $16.86 | 2023 | Brukinsa |
| Immunocore Limited | $16.59 | 2024 | Kimmtrak |
| Sun Pharmaceutical Industries INC. | $14.76 | 2023 | Odomzo, Yonsa |
| Mirati Therapeutics, INC. | $13.34 | 2023 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.